89 related articles for article (PubMed ID: 21037371)
1. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension.
Gambaryan N; Perros F; Montani D; Cohen-Kaminsky S; Mazmanian GM; Humbert M
Eur Respir J; 2010 Nov; 36(5):1209-11. PubMed ID: 21037371
[No Abstract] [Full Text] [Related]
2. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
[TBL] [Abstract][Full Text] [Related]
3. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
4. c-Kit function is necessary for in vitro myogenic differentiation of bone marrow hematopoietic cells.
Xaymardan M; Cimini M; Fazel S; Weisel RD; Lu WY; Martin U; Harvey RP; Li RK
Stem Cells; 2009 Aug; 27(8):1911-20. PubMed ID: 19544423
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
7. Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive.
Tabone-Eglinger S; Calderin-Sollet Z; Pinon P; Aebischer N; Wehrle-Haller M; Jacquier MC; Boettiger D; Wehrle-Haller B
FASEB J; 2014 Oct; 28(10):4441-56. PubMed ID: 25002122
[TBL] [Abstract][Full Text] [Related]
8. Sox4 is required for the survival of pro-B cells.
Sun B; Mallampati S; Gong Y; Wang D; Lefebvre V; Sun X
J Immunol; 2013 Mar; 190(5):2080-9. PubMed ID: 23345330
[TBL] [Abstract][Full Text] [Related]
9. Critical role for c-kit (CD117) in T cell lineage commitment and early thymocyte development in vitro.
Massa S; Balciunaite G; Ceredig R; Rolink AG
Eur J Immunol; 2006 Mar; 36(3):526-32. PubMed ID: 16482516
[TBL] [Abstract][Full Text] [Related]
10. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
11. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
12. Effects of imatinib on bone marrow engraftment in syngeneic mice.
Hoepfl J; Miething C; Grundler R; Götze KS; Peschel C; Duyster J
Leukemia; 2002 Sep; 16(9):1584-8. PubMed ID: 12200667
[TBL] [Abstract][Full Text] [Related]
13. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
14. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
Blom T; Fox H; Angers-Loustau A; Peltonen K; Kerosuo L; Wartiovaara K; Linja M; Jänne OA; Kovanen P; Haapasalo H; Nupponen NN
Int J Cancer; 2008 Aug; 123(4):793-800. PubMed ID: 18506689
[TBL] [Abstract][Full Text] [Related]
15. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
17. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
